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A delicate interplay between the components of the plasminogen
activation (PA) system influences the extent of proteolytic degra-
dation of extracellular matrix. Five major components of the PA
system are: urokinase-type and tissue-type plasminogen activator
(uPA and tPA), plasminogen activator inhibitor type 1 and type 2
(PAI-1 and PAI-2) and a receptor for uPA (uPAR). In several
tumour types increased levels of these components have been
found, and their production is supposed to influence the invasive
and metastasizing behaviour of tumour cells (de Vries et al, 1996;
Andreasen et al, 1997). Clinical studies, mostly using enzyme-
linked immunosorbent assay (ELISA) methods, emphasized the
value of uPA as a prognostic marker and, in addition, showed the
prognostic impact of other PA components in several cancer types
(Kuhn et al, 1994; Duggan et al, 1995; Foekens et al, 1995; Ganesh
et al, 1996; Schmitt et al, 1997). Another, although less validated,
approach to investigate the prognostic significance of these
components is immunohistochemistry (IHC) (Kobayashi et al,
1994; Mulcahy et al, 1994; Hsu et al, 1995; Heiss et al, 1996;
Pappot et al, 1997; Umeda et al, 1997; Ruiter et al, 1998).
ELISA and IHC both have their specific advantages. Regarding
ELISA for the PA components, the measurements are of estab-
lished clinical value, standardization is being attained and a
number of multicenter studies are already subject to quality assur-
ance (Sweep et al, 1998). Furthermore, ELISA methods give an
objective quantification of analyte levels, whereas IHC yields at
best semi-quantitative information. However, IHC allows insight
into tissue heterogeneity. Moreover, the distribution of an antigen
over the different cell types, and therefore the clinical relevance of
expression of an antigen by a particular cell type, can be studied.
Another advantage of IHC is that it can often be performed on both
frozen sections and routinely processed paraffin-embedded tissue
(Ferrier et al, 1998).
In the present paper we compared semi-quantitatively scored
IHC determinations with quantitative ELISA measurements for
uPA, tPA, PAI-1 and uPAR in a panel of cancer lesions of different
origin (breast, lung, colon, cervix and melanoma). In a second
stage, more samples of breast carcinoma and melanoma were
added, and the same kind of analysis was performed on these
cancer types separately. ELISAs were performed on extracts of
multiple thick tumour tissue sections and, to obtain the highest
possible uniformity of test material, IHC was done on adjacent
frozen sections. The degree of concordance of results found with
the two techniques may illuminate the position of the two tech-
niques regarding each other.
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Summary Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information
on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system
in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33
cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly,
the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two
techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of
almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied
between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a
higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from
different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the
two techniques are not directly interchangeable and that their value for clinical purposes may be different.
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MATERIALS AND METHODS
Tissues
Tumour specimens that had been snap-frozen in liquid nitrogen
immediately after surgery and stored at –80°C were obtained from
the tissue bank of the Department of Pathology, University
Hospital Nijmegen, The Netherlands. All specimens were derived
from invasive primary or metastatic tumours, and contained at
least 75% tumour tissue. In the first phase, samples from six lung
carcinomas, six colon carcinomas, six carcinomas of the uterine
cervix, six melanomas and nine breast carcinomas were investi-
gated. Of these specimens, two sets of ten 20-mm thick sections
were cut for analysis by ELISA. Adjacently, 4-mm thick sections
were cut for standard haematoxylin–eosin staining and IHC. In the
second phase, 17 more melanoma and 19 more breast carcinoma
tissues were analysed. Of these samples only one set of ten 20-mm
thick sections were cut for analysis by ELISA plus adjacent 4-mm
thick sections for (immuno)histology.
Tissue extraction
Pooled tissue fragments (10 ´ 20 mm) from one specimen were
pulverized in the presence of 300 ml extraction buffer by means of
a microdismembrator (B Braun Biotech International GmbH,
Melsungen, Germany) at –170°C. After thawing on ice, the
homogenates were centrifuged at 105 000 g for 1 h at 4°C and the
supernatants were stored at –80°C until further analysis in the
ELISAs.
For the set of 33 samples of various cancer types, two buffers
were compared for their extraction efficiency: (i) a phosphate
buffer: 10 mM K2HPO4/KH2PO4, 1.5 mM K2-EDTA, 10 mM
monothioglycerol, 10% (v v–1) glycerol, 10 mM sodium molybdate
(pH = 7.5) (Thorpe, 1987) and (ii) a detergent-containing Tris
buffer: 0.1 M Tris-HCl (pH = 8.1), 1% (w v–1) Triton X-114,
10 mM EDTA, 10 mg ml–1 aprotinin (Behrendt et al, 1990).
For the extra melanoma and breast carcinoma samples, only the
detergent-containing Tris buffer was used for extraction.
ELISAs
Antigen levels of uPA, tPA and PAI-1 were determined using
recently developed ELISAs (Grebenschikov et al, 1997). uPAR
levels were determined using the ELISA as described by Rønne
et al (1995). The ELISAs detect both the free forms and relevant
complexes of the specific component with other components.
Standards, controls and samples were all diluted in phosphate-
buffered saline (PBS) containing 1% bovine serum albumin (BSA)
(Fraction V; Boehringer Mannheim GmbH, Mannheim, Germany)
and 0.1% (v v–1) Tween-20. Incubation was performed overnight at
4°C. As a substrate 0.02% orthophenylenediamine (DAKO,
Glostrup, Denmark)/0.01% hydrogen peroxide was used, and
absorbances were read at 492 nm (reference wavelength 620 nm)
with an automated ELISA reader (AR 2001, Anthos Labtec
Instruments GmbH, Salzburg, Austria). All samples were assayed
in duplicate. ELISA results were expressed per mg of protein.
Protein was quantified with the Bradford method (Bradford, 1976)
using the Bio-Rad reagent (Richmond, CA, USA) with BSA as a
standard. Triton X-114 in a concentration of 1% does not influence
the ELISA determinations and does not interfere with the protein
quantification in tissue extracts (own results).
IHC
Frozen sections of 4 mm thickness were fixed for 10 min in
acetone at room temperature, and immunostaining was performed
as described recently (Ferrier et al, 1998). Briefly, a three-step
staining procedure with peroxidase-conjugated avidin–biotin
complex (Vector Laboratories, Burlingame, CA, USA) was
performed. The primary rabbit antibodies directed against uPA,
tPA, PAI-1 and uPAR as listed in Table 1 were used; biotinylated
goat anti-rabbit immunoglobulin (Vector Laboratories) was used
as secondary antibody. Diaminobenzidine (Sigma, St Louis, MO,
USA) was used as substrate to visualize the immune complexes.
To determine specificity of the immunostaining procedures,
sections were incubated in the absence of the primary antibody.
Specificity and sensitivity of the antibodies and procedures were
also judged by staining negative and positive tissue control
sections. Moreover, the specificity of most primary rabbit anti-
bodies has previously been secured by affinity absorption studies,
replacement with non-immune serum, and Western blotting
analysis (Ferrier et al, 1998).
IHC results were analysed independently by two observers
(CMF and GNPvM) without foreknowledge of the ELISA values.
Discordances were resolved by joint review. The entire sections
were reviewed and an overall semi-quantitative score, integrating
the extent and intensity of staining of both tumour cells and
stromal cells (fibroblasts, endothelial cells, inflammatory infil-
trating cells as macrophages and lymphocytes), was assessed.
Sections were graded from minimally 0 to maximally 3 as follows:
0, maximally 10% of the section stained weakly positive; 1,
minimally 10% of the section stained weakly positive and maxi-
mally 10% of the section stained moderately or strongly positive;
2, 10–40% of the section stained moderately positive or 10–25%
stained strongly positive; 3, over 40% of the section stained
moderately positive or over 25% of the section stained strongly
positive.
Table 1 Antibodies employed in the different ELISAs, and the subgroup of
antibodies which were used to compare with IHC
PA comp. Antibodya Sourceb Comparison Conc. IHCc
uPA Rb-PAb DCE + 1.3
Ch-PAb DCE –
tPA Rb-PAb DCE + 2.0
Ch-PAb DCE –
PAI-1 Rb-PAb DCE + 1.0
Ch-PAb DCE –
uPAR Rb-PAb FL + 1.5
Clone R2d FL –
Clone R3d FL –
Clone R5d FL –
a Rb = rabbit; Ch = chicken. PAb = polyclonal antibody. The
R-clones are mouse monoclonal antibodies of the IgG1 type. bDCE =
Department of Chemical Endocrinology, University Hospital Nijmegen, The
Netherlands (Grebenschikov et al, 1997); FL = Finsen Laboratory,
Copenhagen, Denmark (Rønne et al, 1991, 1995). cFinal concentration in
mg ml–1 as used for IHC. d R2 is directed against the non-ligand-binding part
of the uPAR molecule. R3 and R5 are directed against the uPA-binding
domain of uPAR (Rønne et al, 1991, 1995).1536 CM Ferrier et al
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Statistical analysis
Spearman’s rank correlations were evaluated for the relations
between (i) ELISA values for each component as found in the two
types of tissue extracts, (ii) ELISA values for the different compo-
nents as found after extraction in detergent containing Tris buffer,
(iii) IHC scores for the different components, and (iv) ELISA
results and IHC scores for each of the four components tested.
The Kruskal–Wallis test for ranks was used for analysing differ-
ences of the mean ranks of ELISA values among the different
scoring categories. P-values ≤ 0.05 were considered significant.
RESULTS
ELISA
Per lesion of the group of 33 tumour samples of various types, one
set of ten consecutive 20-mm thick tissue sections was extracted
with phosphate buffer and another set of such thick tissue sections
was extracted with detergent-containing Tris buffer. The
homogenates were analysed in the ELISAs for uPA, tPA, PAI-1
and uPAR. The detergent-containing Tris buffer extracted higher
amounts of the analytes than the phosphate buffer. The two types
of extracts yielded strongly correlating antigen level measure-
ments for uPA (Spearman’s rank correlation coefficient r = 0.86),
PAI-1 (r = 0.88), tPA (r = 0.86) and uPAR (r = 0.79) with P-values
≤ 0.001.
For the compound group of cancer lesions, the results obtained
per tumour type after extraction in the detergent-containing Tris
buffer are presented in Table 2; these data were used for further
comparisons with IHC. The levels found for uPA and PAI-1 were
lowest in melanoma and breast carcinoma, and highest in lung
carcinoma. The levels of tPA were generally low in all tumour
types. uPAR levels were highest in colon and lung carcinoma and
lowest in melanoma and breast cancer. Overall ELISA results in
the compound group, the melanoma group and the breast cancer
group are shown in Table 3.
For the compound group, the levels of uPA, PAI-1 and uPAR
analysed in the extracts prepared with the detergent-containing
Tris buffer intercorrelated significantly, whereas tPA levels corre-
lated only with PAI-1 in a negative way. Correlations of tPA with
the other components were not significant (Table 4). For the
melanoma group, a significant correlation was found only between
uPA and PAI-1. For the breast cancer group, significant correla-
tions were found between uPA and PAI-1, uPA and uPAR and
between uPA and tPA. Except that tPA correlated positively with
PAI-1 in the melanoma group, all other intercorrelations had the
same sign as shown in Table 4.
Table 2 Descriptive statistics of ELISA results in the compound group. Results are shown per tumour type, obtained after extraction with detergent-containing
Tris buffer. Medians and ranges (in brackets) are expressed in ng analyte mg–1 protein
Lung ca, n = 6 Cervical ca, n = 6 Colon ca, n = 6 Melanoma, n = 6 Breast ca, n = 9
uPA 6.28 (3.33–18.23) 5.03 (2.33–8.72) 3.65 (2.30–8.80) 1.04 (0.62–1.77) 2.67 (0.00–8.96)
tPA 0.51 (0.18–1.07) 1.01 (0.48–9.78) 0.29 (0.13–1.02) 0.43 (0.17–1.93) 0.45 (0.21–8.05)
PAI-1 13.00 (3.75–21.85) 6.46 (2.66–11.26) 4.68 (1.41–10.28) 2.65 (0.94–5.78) 2.35 (1.27–7.71)
uPAR 2.58 (1.39–5.63)a 1.82 (1.04–3.42) 2.58 (1.80–3.50) 0.69 (0.44–3.68) 1.02 (0.34–2.29)
n = number of lesions analysed by ELISA; ca = carcinoma. auPAR results are based on five lung carcinomas.
Table 3 Descriptive statistics of the ELISA values obtained in the compound group, the melanoma and breast carcinoma group after extraction with detergent-
containing Tris buffer. Data are expressed in ng analyte mg–1 protein
33 tumours, compound group 23 melanoma lesions 28 breast carcinoma lesions
Mean ± s.d. Median Range Mean ± s.d. Median Range Mean ± s.d. Median Range
uPA 4.19 ± 3.65 3.28 0.00–18.23 0.87 ± 0.55 0.80 0.16–1.88 2.00 ± 2.09 1.66 0.00–8.96
tPA 1.21 ± 2.21 0.48 0.13–9.78 0.45 ± 0.44 0.29 0.03–1.93 0.93 ± 1.68 0.36 0.05–8.05
PAI-1 5.96 ± 5.01 4.55 0.94–21.85 2.68 ± 2.93 1.94 0.40–12.56 1.94 ± 1.99 1.35 0.14–7.71
uPAR 1.95 ± 1.26a 1.84a 0.34–5.63a 2.09 ± 2.43 1.30 0.26–11.49 1.14 + 0.57 0.98 0.34–2.82
aThirty-two instead of 33 tumour samples were analysed by ELISA.
Table 4 Spearman’s rank correlation coefficients (r) between PA
components as determined by ELISA (right upper part of the Table) and by
IHC (left lower part of the Table) in the compound group
uPA tPA PAI-1 uPAR
uPA r = –0.18 r = 0.65 r = 0.74
P = 0.32 P = 0.0001 P = 0.0001
tPA r = –0.22 r = –0.38 r = –0.22
P = 0.22 P = 0.03 P = 0.22
PAI-1 r = 0.64 r = –0.05 r = 0.48
P = 0.0001 P = 0.78 P = 0.006
uPAR r = 0.74 r = –0.29 r = 0.58
P = 0.0001 P = 0.10 P = 0.0004Immunohistochemistry and ELISA 1537
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IHC
Sections adjacent to those analysed in the ELISAs were stained for
uPA, tPA, PAI-1 and uPAR. The antibodies used were also incor-
porated in the ELISAs. In an earlier study we found that different
primary antibodies (monoclonal and polyclonal) directed against
the same component yielded comparable staining patterns,
although intensities varied (Ferrier et al, 1998). The highest
staining intensities were obtained with the rabbit polyclonal anti-
bodies that were used for the present study. For the compound
tumour group, scoring results are presented in Table 5. Table 6
summarizes the scoring results for the melanoma group and the
breast carcinoma group. Figure 1 shows some examples of IHC
stainings. Staining patterns differed among various tumour types
and also among different cases of the same tumour type. Sections
either showed isolated tumour cell positivity, isolated stromal cell
positivity, complete negativity or combined positivity of stromal
and tumour cells. Moreover, positivity was often heterogeneous
within different areas of the same tumour sample. For uPA we
found abundant stromal cell staining among all tested cancer
types; tumour cell staining was seen very scarcely in breast carci-
nomas and colon carcinomas, whereas some of the melanomas,
lung and cervical carcinomas showed abundant tumour cell reac-
tivity. For PAI-1, substantial stromal cell staining was seen among
all tumour types, whereas tumour cell staining was only prominent
in some of the melanomas, breast and lung carcinomas. For tPA,
the majority of cases showed weak immunoreactivity of tumour
and/or stromal cells. uPAR stromal cell and tumour cell positivity
was striking among all the tumour types. Control sections on
which the first antibody was omitted showed no immunostaining,
and all control tissue sections showed the correct staining pattern.
In the compound group, strong statistically significant correla-
tions were found between the scores for uPA, PAI-1 and uPAR,
whereas tPA did not correlate significantly with any of the other
components (Table 4). For melanoma and breast carcinoma,
significant correlations were found between uPA and PAI-1, and
between uPA and uPAR. The correlation coefficients between tPA
and the other components were negative for all tumour groups,
whereas the other components intercorrelated positively.
IHC versus ELISA
For the compound group of 33 tumour samples (32 samples for
uPAR), the melanoma group and the breast carcinoma group, the
IHC scores were compared with the ELISA values by calculation
of Spearman correlation coefficients. Correlation coefficients
varied between 0.41 and 0.78, and were all statistically significant
(Table 7). Figures 2 and 3 show the IHC scores and the corre-
sponding ELISA values, with the median ELISA value for each
scoring category. For each group, the median ELISA value
increased with increasing score category. All Kruskal–Wallis tests
for comparison of the mean ranks of the ELISA values over the
different IHC scoring categories were significant in the compound
group. In the melanoma and breast carcinoma groups, these tests
were significant for only some of the components (melanoma: for
uPAR; breast carcinoma: for uPA, PAI-1 and uPAR).
DISCUSSION
In the present study we compared the antigen levels of uPA, tPA,
PAI-1 and uPAR in tissue extracts as determined by ELISA with
the expression in corresponding IHC-stained cryostat sections as
semi-quantitated by microscopic observation. Such an analysis
was done on a compound group consisting of various tumour
types, a melanoma group and a breast cancer group.
First we addressed the preparation of extracts for the ELISAs.
We compared phosphate buffer and detergent-containing Tris
Table 5 IHC scoring results of the compound group, showing number of
lesions per tumour type as classified in the particular scoring classes.
Sections were stained with rabbit polyclonal antibodies
Lung Cervix Colon Melanoma Breast
Score n = 6 n = 6 n = 6 n = 6 n = 9
uPA 0 0 0 0 0 0
100 0 3 3
211 2 1 2
355 4 2 4
tPA 0 2 1 2 1 4
133 4 5 5
212 0 0 0
300 0 0 0
PAI-1 0 0 0 0 0 0
102 2 3 3
222 4 1 3
342 0 2 3
uPAR 0 0 0 0 0 0
101 0 3 2
242 4 2 4
323 2 1 3
n = number of lesions tested for the specific tumour type.
Table 6 IHC scoring results of melanoma and breast carcinoma groups.
Distribution over the different scoring categories are given in percentages of
the total of 23 melanoma and 28 breast carcinoma lesions
Melanoma/breast carcinoma
0 123
uPA 0/0 35/36 52/36 13/28
tPA 17/36 53/61 17/3 13/0
PAI-1 4/18 65/53 22/18 9/11
uPAR 0/0 22/7 30/39 48/54
Table 7 Spearman’s rank correlation coefficients (r) and P-values for the
relationships between the ELISA values and the IHC scores as found in the
compound group, the melanoma group and the breast carcinoma group
Compound group Melanoma Breast carcinoma
rP -value rP -value rP -value
uPA 0.68 0.0001 0.50 0.014 0.78 0.0001
tPA 0.54 0.0011 0.41 0.049 0.44 0.018
PAI-1 0.66 0.0001 0.46 0.028 0.77 0.0001
uPARa 0.60 0.0003 0.60 0.0026 0.49 0.0076
aThe correlation coefficient of uPAR was based on 32 tumour samples.1538 CM Ferrier et al





Figure 1 IHC staining results showing different allocated scores and different distribution of positivity. Sections were stained with rabbit polyclonal antibodies.
(A, B, C) A lung carcinoma stained for uPA, uPAR and tPA respectively. (D, E, F) A melanoma metastasis stained for PAI-1, uPAR and tPA respectively. (A and
D) Sections with score = 3; (B and E) stainings with score = 2; (C and E) stainings with score = 1. (A, B and C) Show a combination of tumour cell and stromal
cell positivity, with (A) strong and (B and C) moderate staining intensity. In (C) only a small fraction of tumour and stromal cells are positive. (D) Shows strong
positivity of the extracellular matrix; (E) presents intense positivity of the stromal cells, but these positive cells cover the minority of the section. (F) Shows weak
tumour cell staining. Bar = 50 mm, magnification is the same for all photographs. A colour reproduction of the Figure can be obtained from the corresponding
authorImmunohistochemistry and ELISA 1539
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buffer and found the latter most successful in extracting uPA, tPA,
PAI-1 and uPAR out of tumour tissue. This is in agreement with
previous observations (Rønne et al, 1995) and also with the
concept that detergent-containing buffers are effective for extrac-
tion of membrane components and membrane-associated mole-
cules (Behrendt et al, 1990; de Witte et al, 1997), as in our
experiments for uPAR and uPA. Although the ELISAs were
performed on extracts of a few tissue sections only (10 ´ 20 mm),
all but one of the measurements were above the detection limit
when the detergent-containing Tris buffer was used. This demon-
strates the possibility to perform ELISAs on very small amounts of
tissue, likely attributable to an efficient tissue extraction procedure
and the use of sensitive ELISAs. For the comparison with IHC, we
used the ELISA results obtained on extracts prepared with deter-
gent-containing Tris buffer because of the high recovery obtained
with this buffer for each of the components.
Both with ELISA and IHC, many correlations were found
among the different PA components, which is in agreement with
current knowledge (Rønne et al, 1995; Pappot et al, 1997).
Analysing the compound group of 33 lesions, we found correla-
tions from 0.54 to 0.68 for uPA, tPA, PAI-1 and uPAR between the
expression levels as determined by ELISA and IHC. Although
these correlation coefficients are statistically highly significant,
there is a partial overlap of ELISA values from the different
scoring classes (Figure 2). Hence, for individual tumour cases the
relation between ELISA and IHC is ambiguous. This indicates that
the two techniques are not directly interchangeable and that their
value for clinical purposes may be different. This was reconfirmed
by the analysis of extended groups of melanoma and breast cancer
lesions; these groups also showed considerable overlap (Figure 3).
Correlation coefficients between ELISA and IHC results were of
the same order as in the compound group in case of breast carci-
noma and somewhat lower in case of melanoma.
We considered several aspects to optimize comparison between
the results of the two techniques. Firstly, ELISA and IHC were
performed on consecutive tissue sections which minimized the
effect of tissue heterogeneity. To that end, IHC had to be done on





























































































Figure 2 Correlations between ELISA values and IHC scores for the compound group. u u = lung carcinoma; n n = colon carcinoma; s s = melanoma; l =
cervical carcinoma; ´ = breast carcinoma; — — = median value per scoring category1540 CM Ferrier et al
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performed on paraffin sections. Secondly, IHC was performed
with antibodies that were also used in the ELISAs, which is advan-
tageous to obtain good correlations because of uniform epitope
recognition. Thirdly, both with ELISA and IHC all samples of the
compound group were analysed in one run, evidently reducing
inter-assay variations. The subsequently studied melanoma and
breast carcinoma samples were also analysed in one run.
Complete agreement was not attained despite the considerations
mentioned above. A possible explanation for the discrepancies is
that fractions of a component, as a result of divergent presentation
of epitopes in tumour tissue extracts and in tissue sections, may be
detected with different efficiencies by ELISA and IHC. For
example, during tissue processing new complexes between
components may form while pre-existing complexes may disso-
ciate (de Witte et al, 1997; Pappot et al, 1997). Moreover, both the
catching and detecting antibodies in the ELISAs exert selection,
whereas in IHC only one antibody selects the antigenic determi-
nants. Another point is that, in IHC, estimation of protein expres-
sion levels above the level causing maximum staining is
impossible, whereas with ELISA discrimination is possible even
among very high analyte concentrations.
Only a few other studies have paid attention to the relationship
between ELISA and IHC for one or more components of the PA
system. Significant correlations between IHC scores and ELISA
values were found for uPA in primary breast carcinoma lesions
(Jänicke et al, 1990) and colon carcinoma (Sier et al, 1991), for
uPA and PAI-1 in cervical cancer of the uterus (Kobayashi et al,
1994) and lymph node metastases of breast cancer but not in
primary breast cancer (Christensen et al, 1996), and for PAI-1 but
not for uPAR in non-small-cell lung cancer (Pappot et al, 1997).
Some of the above mentioned studies described IHC on paraffin
sections (Jänicke et al, 1990; Sier et al, 1991; Kobayashi et al,
1994) whereas others, like us, performed IHC on frozen tissue
(Christensen et al, 1996; Pappot et al, 1997). Correlation coeffi-
cients reported range from 0.49 to 0.80. However, the correlation
coefficients found by different groups are difficult to compare,
among others since different IHC scoring methods and different



































































































Figure 3 Correlations between ELISA values and IHC scores for the melanoma and breast cancer group. s s = melanoma; ´ = breast carcinoma; — — = median
value per scoring categoryImmunohistochemistry and ELISA 1541
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At present, ELISA methods are preferred for assessment of the
PA components, at least by their more extensively proven clinical
value, unequivocal interpretation and the ongoing of quality assur-
ance programmes. Nevertheless, the insight into tissue distribution
and the ample availability of paraffin tissue render that ultimately
both IHC and ELISA may be used complementarily, depending on
the amount of tissue and the way of fixation available. Future
studies comparing the prognostic impact of both approaches should
further position the two techniques in the context of clinical use.
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